TippingPoint Biosciences
Develops novel drug discovery platform to target epigenetic targets in pediatric brain cancer
$4.5MSeed
Role not disclosedS
SOSV
sosv.com ↗Activity from announced rounds
Activity in this selectionUnited States · Mar 31, 2026 · Mar 1, 2026
SOSV invests in deep technology at pre-seed, focusing on human and planetary health and providing founders with laboratory, engineering and company-building facilities.
Its locations in New York, Newark and San Francisco combine workspace with specialist resources for developing scientific and physical products. The model is designed for founders who need experimental facilities alongside early capital.
Its work spans biotechnology, industrial production and climate-related technologies. SOSV also organises investor matchups and a Deep Tech Summit, connecting companies with prospective financing partners as they move from technical development toward commercialisation.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- — 4 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $24M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionRyboDyn
Decodes the dark proteome using an AI-powered novel sequencing and discovery platform to reveal novel cancer targets
$10MSeed
Role not disclosedSequential
Develops non-invasive multi-omic testing platform for skin health and cosmetics using AI and microbiome analysis
$3.5MSeed
Role not disclosedSurf Therapeutics
Develops non-invasive ultrasound neuromodulation therapies to treat immune-mediated diseases
$6MSeed
Role not disclosed